Stay updated with breaking news from Activating Construct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its price objective trimmed by HC Wainwright from $7.00 to $4.50 in a report released on Wednesday morning, The Fly reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Harpoon Therapeutics’ Q1 2023 earnings at ($0.52) EPS, Q2 2023 earnings […]
Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) – Equities researchers at HC Wainwright issued their FY2027 EPS estimates for Harpoon Therapeutics in a research note issued to investors on Wednesday, March 29th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.23 per share for the year. HC Wainwright has a “Buy” rating […]
HPN217 and HPN328 enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million preferred... | March 27, 2023
07.02.2023 - SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB ...
11.12.2022 - Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses ... Seite 1